“I suspect that the lack of demonstrable clinical effectiveness will mean that lecanemab will not be taken up widely within healthcare systems around the world,” said Professor Robert Howard (UCL Psychiatry) about a newly developed drug against Alzheimer’s disease.
Read: FT (£), More: Express
Close
